SherrardD.J., BaylinkD.J., WergedalJ.E., MaloneyN.A.Quantitative histological studies on the pathogenesis of uremic bone disease.J Clin Endocrinol Metab1974; 39: 119–35.
2.
WitmerG., MargolisA., FontaineO., FritschJ., LenoirG., BrayerM.Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure.Kidney Int1976; 10: 395–408.
3.
MoriniereP., Cohen-SolalM., BelbrikS., BoudailliezB., MarieA., WesteelP.F.Disappearance of aluminic bone disease in a long-term asymptomatic dialysis population restricting Al(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum.Nephron1989; 53: 93–101.
4.
MathiasR., SaluskyI.B., HarmonW., ParedesA., EmansJ., SegreG.Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital.J Am Soc Nephrol1993; 3: 1938–46.
5.
SaluskyI.B., RamirezJ.A., OppenheimW., GalesB., SegreG.V., GoodmanW.G.Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD.Kidney Int1994; 45: 253–8.
6.
SherrardD.J.Aplastic bone: a non-disease of medical progress.Adv Ren Replace Ther1995; 2: 20–3.
7.
WangM., HerczG., SherrardD.J., MaloneyN.A., SegreG.V., PeiY.Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.Am J Kidney Dis1995; 26: 836–44.
AndressD., HerczG., KoppJ., EndresD.B., NorrisK.C., CoburnJ.W.Bone histomorphometry of renal osteodystrophy in diabetic patients.J Bone Miner Res1987; 2: 525–31.
12.
SugimotoT., RitterC., MorrisseyJ., HayesC., SlatopolshyE.Effects of high concentrations of glucose on PTH secretion in parathyroid cells.Kidney Int1990; 37: 1522–7.
13.
JaraA., BoverJ., FelsenfeldA.J.Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure.Kidney Int1995; 47: 1746–51.
NgA., HerczG., KandelR., GrynpasM.D.Association between fluoride, magnesium, aluminum and bone quality in renal osteodystrophy.Bone2004; 34: 216–24.
16.
MoriniereP., VinatierI., WesteelP., CohemsolalM., BelbrikS., AbdulmassihZ.Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation.Nephrol Dial Transplant1988; 3: 651–6.
17.
MorrisseyJ., SlatopolskyE.Effect of aluminum on parathyroid hormone secretion.Kidney Int Suppl1986; 18: S41–4.
18.
GoodmanW.G.Experimental aluminum-induced bone disease: studies in vivo.Kidney Int Suppl1986; 18: S32–6.
19.
SherrardD.J.Aluminum and renal osteodystrophy.Semin Nephrol1986; 6: 5–11.
20.
Avila-DiazM., MatosM., Garcia-LopezE., PradoM.C., Castro-VazquezF., VenturaM.J.Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.Perit Dial Int2006; 26: 78–84.
21.
MakR.H., TurnerC., ThompsonT., PowellH., HaycockG.B., ChantlerC.Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.Br Med J (Clin Res Ed)1985; 291: 623–7.
22.
IndridasonO.S., QuarlesL.D.Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.Kidney Int2000; 57: 282–92.
23.
TamanahaK., MakR., RigdenS., TurnerC., StartK.M., HaycockG.B.Long-term suppression of hyperparathyroidism by phosphate binders in uremic children.Pediatr Nephrol1987; 1: 145–9.
24.
SanchezC.P., KuizonB.D., AbdellaP.A., JuppnerH., SaluskyI.B., GoodmanW.B.Impaired growth, delayed ossification, and reduced osteoclastic activity in the growth plate of calcium-supplemented rats with renal failure.Endocrinology2000; 141: 1536–44.
25.
CozzolinoM., LuY., FinchJ., SlatopolskyE., DussoA.S.p21WAF1 and TGF- mediate parathyroid growth arrest by vitamin D and high calcium.Kidney Int2001; 60: 2109–17.
26.
GoodmanW.G., GoldinJ., KuizonB., YoonC., GalesB., SiderD.Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis.N Engl J Med2000; 342: 1478–83.
27.
BlockG.A.Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients.Clin Nephrol2000; 54: 318–24.
28.
OhJ., WunschR., TurzerM., BahnerM., RaggiP., QuerfeldV.Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure.Circulation2002; 106: 100–5.
29.
KurzP., Monier-FaugereM-C, BognarB., WernerE., RothP., VlachojannisJ.Evidence for abnormal calcium homeostasis in patients with adynamic bone disease.Kidney Int1994; 46: 855–61.
30.
BroS., BrandiL., DaugaardH., OlgaardK.Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize?Perit Dial Int1997; 17: 554–9.
31.
WeinreichT., RitzE., Passlick-DeetjenJ.Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.Perit Dial Int1996; 16: 260–8.
32.
KurzP., TsobanelisT., BrunkhorstR., RothP., WernerE., SchoeppeW.Calcium kinetic studies in patients on CAPD: improvement of secondary hyperparathyroidism without concomitant improvement of calcium turnover.Perit Dial Int1997; 17: 59–65.
33.
SilbermannM., MirskyN., LevitanS., WeismanY.The effect of 1,25-dihydroxyvitamin D3 on cartilage growth in neonatal mice.Metab Bone Dis Relat Res1983; 4: 337–45.
KlausG., Meinhold-HeerleinR., MildeP., RitzE., MehlsO.Effect of vitamin D on growth cartilage cell proliferation in vitro.Pediatr Nephrol1991; 5: 461–6.
36.
GoodmanW.G., RamirezJ.A., BelinT.R., RitzE., MehlsO.Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.Kidney Int1994; 46: 1160–6.
37.
SaluskyI.B., KuizonB.D., BelinT.R., RamirezJ.A., GalesB., SegreG.V.Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration.Kidney Int1998; 54: 907–14.
38.
NKF: K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease.Am J Kidney Dis2005; 46(Suppl 1): S1–121.
39.
SlatopolskyE., BerkobenM., KelberJ., BrownA., DelmezJ.Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism.Kidney Int Suppl1992; 42: S43–9.
40.
CoburnJ., MaungH., ElangovanL., GermainM.J., LindbergJ.S., SpragueS.M.Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.Am J Kidney Dis2004; 43: 877–90.
41.
MartinK.J., GonzalezE.A., GellensM., HammL.L., AbboudH., LindbergJ.19-nor-1-α25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.J Am Soc Nephrol1998; 9: 1427–32.
42.
MaungH.M., ElangovanL., FrazaoJ.M., BowerJ.D., KelleyB.J., AcchiardoS.R.Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1α–hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.Am J Kidney Dis2001; 37: 532–43.
43.
HofbauerL.C., HeufelderA.E.Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.Eur J Endocrinol1998; 139: 152–4.
Avbersek-LuznikI., BalonB.P., RusI., MarcJ.Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?Nephrol Dial Transplant2005; 20: 566–70.
46.
Avbersek-LuznikI., MalesicI., RusI., MarcJ.Increased levels of osteoprotegerin in hemodialysis patients.Clin Chem Lab Med2002; 40: 1019–23.
47.
BrossardJ-H, CloutierM., RoyL., LepageR., Gascon-BarreM., D'AmourP.Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values.J Clin Endocrinol Metab1996; 81: 3923–9.
48.
D'AmourP., BrossardJ-H, RousseauL., RoyL., GaoP., CantorT.Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism.Clin Chem2003; 49: 2037–44.
49.
SlatopolskyE., FinchJ., ClayP., MartinD., SicardG., SingerG.A novel mechanism for skeletal resistance in uremia.Kidney Int2000; 58: 753–61.
50.
LehmannG., SteinG., HullerM., SchemerR., RamakrishnanK., GoodmanW.G.Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.Kidney Int2005; 68: 1206–14.
51.
SaluskyI.B., GoodmanW.G., KuizonB.D., LavigneJ.R., ZahranikR.J., GalesB.Similar predictive value of bone turnover using the first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.Kidney Int2003; 63: 1801–8.
52.
BoverJ., JaraA., TrinidadP., RodriguezM., Martin-MaloA., FelsenfeldA.J.The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia.Kidney Int1994; 46: 310–17.
53.
GalceranT., MartinK.J., MorrisseyJ.J., SlatopolskyE.Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone.Kidney Int1987; 32: 801–7.
54.
QuarlesL.D., LobaughB., MurphyG.Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.J Clin Endocrinol Metab1992; 75: 145–50.
55.
NKF.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis2003; 42(Suppl 3): S1–S201.
56.
PictonM., MooreP.R., MawerE.B., HoughtonD., FreemontA.J., HutchisonA.J.Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure.Kidney Int2000; 58: 1440–9.
57.
CoenG., BallantiP., BonucciE., CalabriaS., CentorrinoM., FassinoV.Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients.Nephrol Dial Transplant1998; 13: 2294–302.
58.
ChuP., ChaoT-Y, LinY-F, JanckilaA.J., YamL.T.Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.Am J Kidney Dis2003; 41: 1052–9.
59.
CocoM., RushH.Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone.Am J Kidney Dis2000; 36: 1115–21.
60.
AtsumiK., KushidaK., YamazakiK., ShimizuS., OhmuraA., InoueT.Risk factors for vertebral fractures in renal osteodystrophy.Am J Kidney Dis1999; 22: 287–93.
61.
UbaraY., TagamiT., NakanishiS., SawaN., HoshinoJ., SuwabeT.Significance of minimodeling in dialysis patients with adynamic bone disease.Kidney Int2005; 68: 833–9.
AvramM.M., MittmanN., MyintM.M., FeinP.Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation.Am J Kidney Dis2001; 38: 1351–7.
64.
KuizonB.D., GoodmanW.G., JuppnerH., BoechatI., NelsonP., GalesB.Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD.Kidney Int1998; 53: 205–11.
65.
SalemM., SanchezC., KuizonB., GalesB., GoodmanW.G., SaluskyI.B.Renal bone diseases in children with chronic renal failure [Abstract].J Am Soc Nephrol1998; 9: 549A.
66.
WallerS.C., RidoutD., CantorT., ReesL.Parathyroid hormone and growth in children with chronic renal failure.Kidney Int2005; 67: 2338–45.
67.
SaluskyI.B., GoodmanW.G., SahneyS., GalesB., PerillouxA., WangH.J.Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.J Am Soc Nephrol2005; 16: 2501–8.
68.
SlatopolskyE.A., BurkeS.K., DillonM.A.RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone.Kidney Int1999; 55: 299–307.
69.
BehetsG.J., VerberckmoesS.C., OsteL., BervoetsA.R., SalomeM., CoxA.G.Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.Kidney Int2005; 67: 1830–6.
70.
LacourB., LucasA., AuchèreD., RuellanN., de Serre PateyN.M., DruekeT.B.Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.Kidney Int2005; 67: 1062–9.
71.
WeinrichT., Passlick-DeetjenJ., RitzE.Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial.Am J Kidney Dis1995; 25: 452–60.
